---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-033834"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2023-09-27T23:59:59+00:00"
generated_at: "2026-06-10T08:05:18.112439+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NanoVibronix receives NHS Drug Tariff approval for UroShield actuators; contract extended to 4 years

## Summary
- NHS Drug Tariff approval enables full reimbursement of UroShield actuators starting November 1, 2023 for clinicians to prescribe.
- NHS Supply Chain contract extended up to four years via UK distribution partner Peak Medical Limited.
- CEO Brian Murphy: reimbursement removes critical barrier; expects increased unit sales and production to meet demand.
- UroShield is used for preventing Catheter-Associated Urinary Tract Infections (CAUTIs) in patients with indwelling catheters.
- Patients can now receive full UroShield system with NHS covering cost, not patient.

## SEC filing metadata
- accession: 0001493152-23-033834
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2023-09-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315223033834/0001493152-23-033834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315223033834/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-033834
- JSON: https://secwatch.observer/filing/0001493152-23-033834.json
- Plain text: https://secwatch.observer/filing/0001493152-23-033834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.